BEVACIZUMAB Safety Questions, BEVACIZUMAB Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about BEVACIZUMAB. Our extensive database of BEVACIZUMAB adverse events and BEVACIZUMAB warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about BEVACIZUMAB
BEVACIZUMAB Safety Reports
Total BEVACIZUMAB reports: 874.BEVACIZUMAB FDA safety alerts: 2004 2005 2006 2007 .
Reported deaths: 194 Reported hospitalizations: 649.
Take BEVACIZUMAB Side Effects Survey or Share Your BEVACIZUMAB Story. Read More Here.
Showing 1-75 of 874 Next >
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 15, 2007. Female patient, weighting 121.3 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, disease progression. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, OXALIPLATIN. Patient died on 01/21/2007.BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Mar 02, 2007. Female patient, 75 years of age, was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, body temperature increased, dysstasia, fall, heart rate decreased, muscular weakness, spinal osteoarthritis. BEVACIZUMAB dosage: 760 MG, Q2W, INTRAVENOUS. During the same period patient was treated with IRINOTECAN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 02, 2007. Female patient, 57 years of age, was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: condition aggravated, neutropenia, sinusitis, sinusitis fungal. BEVACIZUMAB dosage: 718 MG, Q2W, INTRAVENOUS. During the same period patient was treated with ADRIAMYCIN PFS, CYTOXAN, PACLITAXEL, NEULASTA, CETIRIZINE, MONTELUKAST. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Mar 19, 2007. Female patient, weighting 123.2 lb, was diagnosed with metastasis and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cardiac arrest, encephalopathy, haemoptysis, haemorrhage. BEVACIZUMAB dosage: 10 MG/KG Q2 WEEKS IV. During the same period patient was treated with BEVACIZUMAB N. Patient was hospitalized and became disabled. Patient died on 03/03/2007.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Mar 02, 2007. Male patient, 37 years of age, weighting 174.4 lb, was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DECADRON, SEROQUEL, KEPPRA, PROTONIX, VITAMIN, ALLEGRA, TRILEPTAL. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Mar 20, 2007. Female patient, weighting 136.0 lb, was diagnosed with pancreatic carcinoma metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis, pulmonary embolism. BEVACIZUMAB dosage: 15MG/KG EVERY 3 WEEKS IV DRIP. During the same period patient was treated with ERLOTINIB. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Mar 22, 2007. Male patient, 71 years of age, weighting 177.0 lb, was diagnosed with tonsil cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, pneumonitis. BEVACIZUMAB dosage: 10 MG/KG Q 2 WEEKS IV. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE, CISPLATIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 22, 2007. Male patient, 71 years of age, weighting 183.0 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cystitis, haemorrhage. BEVACIZUMAB dosage: 10 MG/KG DAYS 1+15 IV. During the same period patient was treated with PEMETREXED, ERLOTINIB, LIPITOR, FLOMAX, VASOTEC, ACTOS, CLARITIN, CHLORTHALID. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Mar 22, 2007. Male patient, 71 years of age, weighting 177.0 lb, was diagnosed with tonsil cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: neutropenia, pyrexia. BEVACIZUMAB dosage: 10 MG/KG Q 2 WEEKS IV. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE, CISPLATIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 12, 2007. Male patient, 68 years of age, weighting 160.7 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: asthenia, confusional state, leukoencephalopathy. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, CAROBPLATIN. Patient died on 03/09/2007.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 13, 2007. Male patient, 69 years of age, weighting 172.0 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal tenderness, erosive oesophagitis, nausea, weight decreased. BEVACIZUMAB dosage: 1395 MG, Q3W, INTRAVENOUS. During the same period patient was treated with CARBOPLATIN, DEXAMETHASONE, REGLAN, PACLITAXEL, EMEND, KYTRIL, PHENERGAN, PRILOSEC. Patient was hospitalized and became disabled. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 12, 2007. Male patient, 63 years of age, was diagnosed with neoplasm malignant and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: bronchial obstruction, chronic obstructive pulmonary disease, condition aggravated, diverticular perforation, lung infection pseudomonal, lung neoplasm, pulmonary thrombosis, respiratory distress. BEVACIZUMAB dosage: 15 MG/MKG, Q3W, INTRAVENOUS. During the same period patient was treated with ALIMTA, LEVOTHYROXINE, VANCOMYCIN HYDROCHLORIDE, FORTAZ, FLAGYL, PROTONIX, NORVASC, PULMICORT. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 12, 2007. Male patient, 68 years of age, weighting 160.7 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: brain scan abnormal, cerebral arteriosclerosis, condition aggravated, depressed level of consciousness, fall, leukoencephalopathy. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, LOVASTATIN, ATENOLOL, CARBOPLATIN, LISINOPRIL, ASPIRIN, LANTUS, HUMALOG. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Mar 26, 2007. Male patient, weighting 233.0 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: arterial haemorrhage, rectal haemorrhage. BEVACIZUMAB dosage: unknown. Patient was hospitalized. Patient died on 03/19/2007.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Mar 23, 2007. Female patient, 58 years of age, weighting 163.1 lb, was diagnosed with renal cancer metastatic, metastases to lung and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cerebral infarction, fall, wrist fracture. BEVACIZUMAB dosage: 740 MG IV X 1. During the same period patient was treated with PROLEUKIN, ZETIA, PROTONIX, SYNTHROID, IBUPROFEN, NORVASC, BACOLFEN, TRAMADOL. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from SINGAPORE on Mar 16, 2007. Male patient, 54 years of age, was diagnosed with colon cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: bronchopulmonary aspergillosis, neutropenia. BEVACIZUMAB dosage: unknown. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL. Patient recovered.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Mar 29, 2007. Female patient, 68 years of age, was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: glioblastoma multiforme, haematochezia, haemoglobin decreased, malignant neoplasm progression, peripheral motor neuropathy, sedation. BEVACIZUMAB dosage: 10 MG/KG. During the same period patient was treated with ERLOTINIB, TOPROL, TIMOLOL MALEATE, NEXIUM, COUMADIN, DEXAMETHASONE. Patient was hospitalized. Patient died on 03/18/2007.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 13, 2007. Female patient, 65 years of age, weighting 108.0 lb, was diagnosed with lung neoplasm malignant and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: chest pain, sinus tachycardia. BEVACIZUMAB dosage: 743 MG, Q3W, INTRAVENOUS. During the same period patient was treated with TAXOL, CARBOPLATIN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 21, 2007. Male patient, 71 years of age, weighting 181.9 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cystitis, haematuria, haemorrhage. BEVACIZUMAB dosage: 10 MG/KG, DAYS 1+15, INTRAVENOUS. During the same period patient was treated with ERLOTINIB, PEMETREXED, LIPITOR, FLOMAX, ENALAPRIL MALEATE, ACTOS, CLARITIN, ATENOLOL. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 23, 2007. Male patient, 60 years of age, weighting 225.1 lb, was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abnormal behaviour, deep vein thrombosis, hydrocephalus, neutrophil count decreased, pneumonia, pulmonary embolism, urinary tract infection. BEVACIZUMAB dosage: unknown. During the same period patient was treated with IRINOTECAN, LEVAQUIN, THIAMINE HYDROCHLORIDE, DEXAMETHASONE, HEPARIN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 19, 2007. Male patient, 68 years of age, weighting 160.7 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: arteriosclerosis, asthenia, bacteria urine identified, blood glucose increased, cerebrovascular disorder, confusional state, depressed level of consciousness, drooling, leukoencephalopathy. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, CARBOPLATIN, LOVASTATIN, ATENOLOL, LISINOPRIL, ASPIRIN. Patient was hospitalized. Patient died on 03/09/2007.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Feb 26, 2007. Male patient, 71 years of age, weighting 172.0 lb, was diagnosed with colon cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: anastomotic complication, dyspnoea, procedural site reaction, respiratory tract irritation, thrombosis, tracheal disorder. BEVACIZUMAB dosage: 5MG/KG Q2W IV. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, LIPITOR, NIASPAN, QUANAPRIL, COREG, HEMOCYTE. Patient was hospitalized. Patient recovered.
Physician from UNITED KINGDOM reported BEVACIZUMAB problem on Mar 19, 2007. Female patient, 63 years of age, was diagnosed with colorectal cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: diarrhoea, infection, sepsis. BEVACIZUMAB dosage: 450 MG, UNK. During the same period patient was treated with CAPECITABINE, IRINOTECAN. Patient was hospitalized. Patient died on 03/19/2007.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 02, 2007. Male patient was diagnosed with anaplastic astrocytoma and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism, tenderness. BEVACIZUMAB dosage: 10 MG/KG. During the same period patient was treated with ERLOTINIB, KEPPRA, LEXAPRO, PROTONIX, DECADRON, DILANTIN. Patient was hospitalized. Patient recovered.
Physician from UNITED KINGDOM reported BEVACIZUMAB problem on Mar 22, 2007. Male patient, weighting 233.7 lb, was diagnosed with colorectal cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal pain, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased, blood lactate dehydrogenase increased, liver function test abnormal, renal function test abnormal. BEVACIZUMAB dosage: 700 MG, 2/WEEK. During the same period patient was treated with CAPECITABINE, OXALIPLATIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Mar 22, 2007. Male patient was diagnosed with colorectal cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: mallory-weiss syndrome. BEVACIZUMAB dosage: 427 MG, QD. During the same period patient was treated with CAPECITABINE, OXALIPLATIN, CETUXIMAB, OMEPRAZOLE. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 03, 2007. Male patient, 72 years of age, weighting 168.0 lb, was diagnosed with lung neoplasm malignant and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: haemoglobin decreased, haemoptysis. BEVACIZUMAB dosage: 1100 MG ONCE IV DRIP. Patient died on 03/23/2007.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Apr 02, 2007. Male patient, weighting 142.0 lb, was diagnosed with colon cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: pleural effusion. BEVACIZUMAB dosage: 330 MG, Q2W. During the same period patient was treated with CETUXIMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, FOSAMAX, ZOCOR, TOPROL, ENALAPRIL MALEATE, AMARYL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 04, 2007. Male patient, weighting 181.9 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: haemorrhage, neoplasm malignant, penile pain. BEVACIZUMAB dosage: 10 MG/KG, DAYS 1+15. During the same period patient was treated with ERLOTINIB, PEMETREXED, LIPITOR, FLOMAX, ENALAPRIL MALEATE, ACTOS, CLARITIN, ATENOLOL. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Mar 20, 2007. Female patient, 27 years of age, was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: medical device complication. BEVACIZUMAB dosage: 15 MG/KG, Q3W, INTRAVENOUS. During the same period patient was treated with CYCLOPHOSPHAMIDE, METHOTREXATE. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 05, 2007. Male patient, 71 years of age, weighting 181.0 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: bladder cancer, haematocrit decreased, haemorrhage, penile pain. BEVACIZUMAB dosage: 10 MG/KG DAYS 1+15 IV. During the same period patient was treated with PEMETREXED, ERLOTINIB, LIPITOR, FLOMAX, VASOTEC, ACTOS, CLARITIN, CHLORTHALID. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 05, 2007. Male patient was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, fall, hyponatraemia, nausea, vomiting. BEVACIZUMAB dosage: 10 MG/KG. During the same period patient was treated with ERLOTINIB, TOPROL, PREVACID, RITALIN, KEPPRA, DECADRON, LOVASTATIN, COLACE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED KINGDOM reported BEVACIZUMAB problem on Apr 08, 2007. Female patient, weighting 88.18 lb, was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: hypovolaemia. BEVACIZUMAB dosage: 10 MG/KG, Q2W. During the same period patient was treated with PACLITAXEL, SKENAN, ACTISKENAN, ZOMETA. Patient died on 01/19/2007.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Apr 08, 2007. Female patient was diagnosed with colon cancer, hypertension and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: angioedema. BEVACIZUMAB dosage: 440 MG, Q2W. During the same period patient was treated with OXALIPLATIN, LEUCOVORIN CALCIUM, GOPTEN, CALTRATE, DILTIAZEM, INDAPAMIDE, ZOTON, NAPROXEN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 04, 2007. Female patient, weighting 132.3 lb, was diagnosed with urinary tract infection, insomnia, bronchitis chronic, hypertension and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cystitis haemorrhagic. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, OXALIPLATIN, KEFLEX, AMBIEN, DECADRON, SPIRIVA, AVALIDE. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 04, 2007. Female patient, weighting 207.2 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: failure to thrive, oesophagitis. BEVACIZUMAB dosage: 10 MG/KG, Q28D. During the same period patient was treated with IRINOTECAN, CARBOPLATIN, VYTORIN, ATACAND, PREMARIN, LUNESTA, MELOXICAM, SERTRALINE. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 03, 2007. Male patient, 26 years of age, was diagnosed with colorectal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: nephritis interstitial. BEVACIZUMAB dosage: 5 MG/KG, Q2W. During the same period patient was treated with MORPHINE. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Mar 26, 2007. Female patient, weighting 166.0 lb, was diagnosed with colorectal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: renal failure acute. BEVACIZUMAB dosage: 565 MG, Q3W. During the same period patient was treated with CAPECITABINE, OXALIPLATIN, LISINOPRIL AND HYDROCHLOROTHIAZIDE, METOPROLOL SUCCINATE, LANTUS, SULAR, LIPITOR, PROCRIT. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 04, 2007. Male patient, weighting 142.0 lb, was diagnosed with hunger, anxiety, nausea and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: diabetic ketoacidosis. BEVACIZUMAB dosage: 5 MG/KG, Q2W. During the same period patient was treated with LEUCOVORIN CALCIUM, FLUOROURACIL, OXALIPLATIN, MEGACE, ALPRAZOLAM, DECADRON, ENDOCET, COMPAZINE. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED KINGDOM on Mar 30, 2007. Male patient, weighting 149.9 lb, was diagnosed with metastatic renal cell carcinoma and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dyskinesia, gait disturbance, gliosis, hemiparesis, speech disorder, strabismus, weight decreased. BEVACIZUMAB dosage: 10 MG/KG, Q2W. During the same period patient was treated with INTERFERON ALPHA, PARACETAMOL, ATACAND, ZOMETA, MOVICOL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Mar 23, 2007. Male patient, 26 years of age, was diagnosed with renal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: nephritis interstitial, renal failure acute. BEVACIZUMAB dosage: 5 MG/KG, Q2W, INTRAVENOUS. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Mar 28, 2007. Male patient was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal distension, agitation, bowel sounds abnormal, constipation, cyanosis, disease progression, dyspepsia, fall, left ventricular failure. BEVACIZUMAB dosage: 1380 MG, QD. During the same period patient was treated with ERLOTINIB, IPRATROPIUM BROMIDE, ASPIRIN, TRIATEC, ADALAT, DAFALGAN, PANTOZOL, HEPARIN. Patient was hospitalized. Patient died on 12/11/2006.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Apr 04, 2007. Female patient, weighting 93.98 lb, was diagnosed with colon cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: pancreatitis. BEVACIZUMAB dosage: 5 MG/KG, 2/MONTH. During the same period patient was treated with CAPECITABINE. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Apr 10, 2007. Male patient, weighting 181.9 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: haemorrhage, neoplasm malignant, penile pain. BEVACIZUMAB dosage: 10 MG/KG, DAYS 1+15. During the same period patient was treated with ERLOTINIB, PEMETREXED, LIPITOR, FLOMAX, ENALAPRIL MALEATE, ACTOS, CLARITIN, ATENOLOL. Patient was hospitalized. Patient recovered.
Physician from BRAZIL reported BEVACIZUMAB problem on Mar 20, 2007. Male patient, 43 years of age, weighting 176.4 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cardiac failure congestive, condition aggravated, dialysis, pneumonia, renal failure acute. BEVACIZUMAB dosage: 1185 MG, Q3W, INTRAVENOUS. During the same period patient was treated with VINORELBINE TARTRATE, LEVOTHYROXINE, CARDURAN, STARLIX, METFORMIN, AMITRIL. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Apr 09, 2007. Female patient, weighting 133.6 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, constipation, nausea, vomiting. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with PEMETREXED, CARBOPLATIN. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Apr 09, 2007. Female patient was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, dizziness, fatigue. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with ERLOTINIB, REGLAN, PROCRIT. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Apr 09, 2007. Female patient, 61 years of age, weighting 116.8 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: hyperbilirubinaemia. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with GEMCITABINE, CARBOPLATIN, FENTANYL, MORPHINE SULPHATE, NEURONTIN, COMPAZINE, DULCOLAX. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 09, 2007. Female patient, 61 years of age, weighting 131.0 lb, was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: chest pain, dyspnoea. BEVACIZUMAB dosage: 620 MG, Q2W. During the same period patient was treated with PACLITAXEL, ATIVAN, COMPAZINE, NEULASTA, ARANESP. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 12, 2007. Female patient, weighting 171.3 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, deep vein thrombosis, pain in extremity. BEVACIZUMAB dosage: 1185 MG. During the same period patient was treated with FLUOROURACIL, CAMPTOSAR, LEUCOVORIN CALCIUM, ARANESP, CRESTOR, DULCOLAX, DYAZIDE, GLYBURIDE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED KINGDOM reported BEVACIZUMAB problem on Apr 03, 2007. Male patient, weighting 149.9 lb, was diagnosed with metastatic renal cell carcinoma and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: gliosis. BEVACIZUMAB dosage: 10 MG/KG, Q2W. During the same period patient was treated with INTERFERON ALPHA, PARACETAMOL, ATACAND, ZOMETA, MOVICOL. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 16, 2007. Male patient was diagnosed with glioblastoma multiforme and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, disease progression, fall, hyponatraemia, nausea, pneumonia, somnolence, vomiting. BEVACIZUMAB dosage: 10 MG/KG. During the same period patient was treated with ERLOTINIB, TOPROL, PREVACID, RITALIN, KEPPRA, DECADRON, LOVASTATIN, COLACE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 10, 2007. Male patient, weighting 145.0 lb, was diagnosed with non-small cell lung cancer, gastrooesophageal reflux disease, prophylaxis, anxiety, dysphagia, hypertension, upper respiratory tract infection and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: tracheitis. BEVACIZUMAB dosage: unknown. During the same period patient was treated with ERLOTINIB, NEXIUM, PLAVIX, LORAZEPAM, CARAFATE, LABETALOL, LEVAQUIN, ADVAIR DISKUS. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 13, 2007. Male patient, weighting 147.7 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal pain lower, abdominal pain upper, cancer pain, inadequate analgesia. BEVACIZUMAB dosage: 1303 MG. During the same period patient was treated with FLUOROURACIL, LEUCOVORIN CALCIUM, ELOXATIN. Patient recovered.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 09, 2007. Male patient, weighting 183.0 lb, was diagnosed with colorectal cancer metastatic, adrenal insufficiency, deep vein thrombosis and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: small intestinal obstruction. BEVACIZUMAB dosage: 465 MG, Q2W. During the same period patient was treated with CETUXIMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, CORTISONE ACETATE, FLUDROCORTISONE ACETATE, COUMADIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Mar 27, 2007. Male patient, 68 years of age, weighting 160.7 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cerebral ischaemia, fall, leukoencephalopathy. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, CARBOPLATIN, LOVASTATIN, ATENOLOL, LISINOPRIL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 11, 2007. Female patient, weighting 119.0 lb, was diagnosed with gallbladder cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: acute myocardial infarction, aortic arteriosclerosis, culture urine positive, mitral valve incompetence, sepsis. BEVACIZUMAB dosage: 10 MG, 2/MONTH. During the same period patient was treated with GEMCITABINE, OXALIPLATIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 11, 2007. Male patient, weighting 152.1 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: hyperhidrosis, pain. BEVACIZUMAB dosage: 350 MG. During the same period patient was treated with ELOXATIN, FLUOROURACIL, LEUCOVORIN CALCIUM. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 09, 2007. Male patient, weighting 160.8 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: cerebral arteriosclerosis. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, CARBOPLATIN, LOVASTATIN, ATENOLOL, LISINOPRIL, ASPIRIN, NITROSTAT, LANTUS. Patient was hospitalized. Patient died on 03/09/2007.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Apr 11, 2007. Female patient, 45 years of age, weighting 136.5 lb, was diagnosed with nasal septum perforation and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: epistaxis, nasal septum perforation, rhinorrhoea. BEVACIZUMAB dosage: 10 MG/KG Q 2 WEEKS IV. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 16, 2007. Female patient, weighting 121.3 lb, was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, disease progression. BEVACIZUMAB dosage: unknown. During the same period patient was treated with DOCETAXEL, OXALIPLATIN. Patient died on 01/21/2007.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 06, 2007. Female patient was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dyspnoea, pleural effusion. BEVACIZUMAB dosage: 15 MG/M2, Q2W. During the same period patient was treated with ARIMIDEX, COLACE, MOTRIN IB, LEVOXYL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 05, 2007. Male patient, 44 years of age, was diagnosed with gastric cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: lymphopenia. BEVACIZUMAB dosage: 5 MG/KG, Q2W. During the same period patient was treated with TAXOTERE, PROTONIX, AMBIEN, ALLEGRA, REMERON, ATIVAN. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED KINGDOM on Apr 02, 2007. Male patient, weighting 198.4 lb, was diagnosed with colon cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: pyrexia. BEVACIZUMAB dosage: 450 MG, Q2W. During the same period patient was treated with OXALIPLATIN, LEUCOVORIN CALCIUM, FLUOROURACIL, ZESTORETIC. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED KINGDOM reported BEVACIZUMAB problem on Apr 03, 2007. Female patient, weighting 203.9 lb, was diagnosed with colorectal cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: subileus. BEVACIZUMAB dosage: 440 MG, Q2W. During the same period patient was treated with CAPECITABINE, OXALIPLATIN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 10, 2007. Male patient, weighting 142.0 lb, was diagnosed with colorectal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: diarrhoea, oedema peripheral, pleural effusion, vomiting. BEVACIZUMAB dosage: 330 MG, QOW. During the same period patient was treated with CETUXIMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, FOSAMAX, ZOCOR, ENALAPRIL MALEATE, AMARYL. Patient was hospitalized. Patient recovered.
Physician from UNITED KINGDOM reported BEVACIZUMAB problem on Apr 03, 2007. Female patient, weighting 123.5 lb, was diagnosed with colorectal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: myocarditis. BEVACIZUMAB dosage: 420 MG, Q3W. During the same period patient was treated with MITOMYCIN, XELODA, LOPERAMIDE, LIDOCAINE, NYSTATIN, PYRIDOXINE. Patient died on 09/01/2006.
BEVACIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 16, 2007. Female patient, weighting 236.6 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary haemorrhage. BEVACIZUMAB dosage: 1620 MG, Q3W. During the same period patient was treated with CARBOPLATIN, TAXOL, ALLOPURINOL, SYNTHROID, WELLBUTRIN, ALBUTEROL, LORTAB, FERROUS GLUCONATE. Patient died on 08/16/2006.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 16, 2007. Male patient, weighting 184.5 lb, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: lung infiltration. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with CARBOPLATIN, PEMETREXED, METOPROLOL SUCCINATE, LIPITOR, NEURONTIN, NORVASC, NEXIUM, DARVOCET. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Apr 16, 2007. Female patient, weighting 195.1 lb, was diagnosed with breast cancer and was treated with BEVACIZUMAB. BEVACIZUMAB dosage: 7.5 MG/KG, Q3W. During the same period patient was treated with DOCETAXEL, TYLENOL, METOPROLOL SUCCINATE, ALLOPURINOL, DECADRON, METFORMIN, ARANESP, PAMIDRONATE DI. Patient died on 11/02/2006.
Consumer or non-health professional from UNITED STATES reported BEVACIZUMAB problem on Apr 17, 2007. Male patient, 75 years of age, weighting 196.2 lb, was diagnosed with non-small cell lung cancer, bone marrow failure and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: asthenia, cough, decubitus ulcer, deep vein thrombosis, diarrhoea, haemoglobin decreased, hyperhidrosis, lung infiltration, oxygen saturation decreased. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with TAXOTERE, OXALIPLATIN, DILAUDID, FILGRASTIM, DURAGESIC, TUSSINEX, PHENERGAN, HYCODAN. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED KINGDOM on Apr 17, 2007. Female patient, weighting 114.2 lb, was diagnosed with colorectal cancer metastatic and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, pyrexia. BEVACIZUMAB dosage: 400 MG, Q3W. During the same period patient was treated with CAPECITABINE, OXALIPLATIN, MOTILIUM, ZOTON, BETALOC, CENTYL K. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Apr 12, 2007. Male patient, 59 years of age, was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: dehydration, oesophageal pain, performance status decreased. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with ERLOTINIB. Patient was hospitalized. Patient recovered.
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Apr 17, 2007. Female patient was diagnosed with non-small cell lung cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal pain, nausea, pneumonia, sepsis. BEVACIZUMAB dosage: 15 MG/KG, Q3W. During the same period patient was treated with DOCETAXEL, OXALIPLATIN, SINGULAIR, DEXAMETHASONE, FLUCONAZOLE, ATIVAN, LISINOPRIL, COMPAZINE. Patient was hospitalized. Patient died on 02/08/2007.
Physician from UNITED STATES reported BEVACIZUMAB problem on Apr 10, 2007. Female patient, 43 years of age, was diagnosed with breast cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: myalgia. BEVACIZUMAB dosage: 818 MG, UNK. During the same period patient was treated with TAXOL, DOXORUBICIN, CYCLOPHOSPHAMIDE, NEULASTA, MEDROL. Patient was hospitalized. Patient recovered.
Showing 1-75 of 874 Next >
This
drug has an active FDA Safety Alert